Significant Percentage of Melanoma Survivors Do Not Protect Themselves From Further Sun Damage

Published Online: Friday, May 17, 2013
Follow Pharmacy_Times:
Research from the Yale School of Medicine revealed that after treatment, a significant portion of melanoma survivors continue to engage in risky sun behavior.

The findings were presented at the American Association for Cancer Research Annual Meeting by lead researcher Anees Chagpar, MD, associate professor of surgery at Yale School of Medicine. Her team evaluated data from the 2010 National Health Interview Survey and compared the sun-protective practices of the 171 self-reported melanoma survivors with those of non-cancer patients.

Despite the fact that melanoma patients were more likely to report using sunscreen, nearly 27% of melanoma survivors reported never wearing sunscreen, and nearly 15% said they never seek shade. In addition, nearly 2% of melanoma survivors reported using a tanning bed within the previous year.

Because visiting a tanning bed is a voluntary behavior, the researchers were surprised to discover that skin cancer survivors continued to put themselves at risk. Chagpar noted that future research will be focused on the motivations behind forgoing adequate skin protection and the potentially addictive nature of tanning. “We’re finding more ways to help patients survive cancer, but we need to make sure they are taking action to prevent relapses,” she said.

Related Articles
Whereas previous research indicated that coffee consumption may protect against nonmelanoma skin cancers, a recent study suggested that drinking coffee could decrease a patient’s risk of developing malignant melanoma as well.
Community pharmacists play a significant role in helping patients to maintain the health of their skin.
The FDA has approved Merck’s Keytruda injection for the treatment of patients with unresectable or metastatic melanoma and disease progression following administration of ipilimumab and, if positive for the BRAF V600 mutation, a BRAF inhibitor.
Keytruda, manufactured by Merck, is indicated for treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and a BRAF inhibitor.
Latest Issues
  • photo
    Pharmacy Times
    Health-System Edition
    Directions in Pharmacy
    OTC Guide
    Generic Supplements
  • photo
    Pharmacy Careers
    Specialty Pharmacy Times